Medical education company Pri-Med said on Tuesday that it has entered into a new partnership with the Brain Aneurysm Foundation (BAF) to deliver "Update in Diagnosis and Management of Intracranial Aneurysms for Primary Health Care Providers" at Pri-Med Midwest in Rosemont, IL on 10 October 2018.
During the medical session, Sepideh Amin-Hanjani, MD, University of Illinois at Chicago, will address how to recognise signs of an aneurysm rupture, when to make a referral and order appropriate imaging, and best practices for educating the patient about the risk factors for aneurysm formation and rupture.
According to the company, one in 50 people in the US has an unruptured brain aneurysm and 30,000 of them rupture every year. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death.
This session will focus on the importance of proper diagnosis and scanning and faculty will discuss treatment options to use in practice to meet the need for early detection of brain aneurysm.
Brain Aneurysm Foundation (BAF) is a non-profit organization dedicated to providing critical awareness, education, support, advocacy, and research funding to reduce the incidence of brain aneurysm ruptures.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA